Skip to main content

Recurrent UTI in Women

At a glance​

  • Assess: confirm recurrent acute cystitis symptoms with pyuria and uropathogenic bacteria; review culture history, pelvic examination, menopausal status, intercourse association and possible incomplete emptying. Obtain urinalysis/culture for symptomatic episodes before treatment when feasible.[3]
  • Options: treat acute episodes with culture-informed short courses. Discuss vaginal estrogen when appropriate, cranberry, methenamine, and continuous or postcoital antibiotic prophylaxis using risks and preferences. D-mannose alone may not prevent recurrence.[3][6]
  • Reconsider the pathway: fever/flank pain, pregnancy, catheter-associated infection, neurogenic dysfunction or a structural abnormality fall outside uncomplicated rUTI guidance. Persistent symptoms after microbiological clearance need another diagnostic explanation.[3]
  • Follow-up: review recurrences, adverse effects and ongoing need for prophylaxis. Do not obtain routine test-of-cure cultures in an asymptomatic patient; repeat cultures for persisting symptoms. Do not routinely add vitamin C to methenamine.[3]

Compare ALTAR and MERIT. Use the linked prescribing hubs for doses, contraindications and drug monitoring.

Recurrent urinary tract infection (rUTI) in women is defined as ≥2 UTIs in 6 months or ≥3 UTIs in 12 months (symptomatic episodes supported by pyuria and uropathogenic bacteria), affecting nearly 25% of women who experience an initial UTI.[1][2] The 2025 AUA / CUA / SUFU update emphasizes symptom-linked diagnosis, antimicrobial stewardship and informed choices among preventive options.[3][4]

Part I: Epidemiology​

Over 50% of adult women experience at least one UTI in their lifetime.[5][1] Among those with a first UTI, approximately 27–44% will experience recurrence within 12 months.[2]

Microbiology. Escherichia coli causes approximately 75–80% of recurrent UTIs. Other common organisms include Enterococcus faecalis, Proteus mirabilis, Klebsiella species, and Staphylococcus saprophyticus, particularly in patients with risk factors for complicated UTI.[5][7]

Part II: Pathophysiology — evolving understanding​

A. Traditional model — fecal-perineal-urethral ascent​

The classic model holds that uropathogenic bacteria from the gastrointestinal tract colonize the periurethral area, ascend the urethra, and cause cystitis. This model explains the association with sexual intercourse, spermicide use, and anatomic factors.[8][4]

B. Intracellular bacterial communities (IBCs) and quiescent intracellular reservoirs (QIRs)​

Experimental models show that UPEC can invade urothelial cells and form intracellular bacterial communities. The reservoir and reactivation sequence below is supported primarily by animal and organoid studies:[9][10][11]

  1. IBCs — UPEC binds to and invades superficial umbrella cells via type 1 pili, then replicates intracellularly to form biofilm-like communities. IBCs are transient and occur primarily during acute infection.[9]
  2. QIRs — after IBC dispersal, bacteria penetrate into deeper, immature urothelial layers where they enter a quiescent, non-replicating state. These QIRs are protected from antibiotics and immune surveillance.[9][12][11]
  3. Reactivation — as immature host cells differentiate and migrate toward the bladder lumen, dormant bacteria can reactivate and seed recurrent infection — potentially weeks to months after the initial episode.[12][11]

Rosen et al. (2007) found evidence consistent with IBC formation in humans, without proving the entire reservoir/reactivation pathway — IBCs were found in 18% (14/80) of urine specimens from women with acute cystitis, and filamentous bacteria (a hallmark of IBC dispersal) were found in 41%.[10] Approximately 35% of clinical UPEC isolates demonstrate quorum-dependent quiescence in vitro.[13]

C. The urinary microbiome paradigm​

Updated models recognize that the bladder harbors a complex microbiome, and interactions between the urinary and vaginal environments and immune mechanisms at the bladder mucosal surface influence infection susceptibility. Postmenopausal women experience microbiome shifts (loss of protective Lactobacillus species) that increase vulnerability to recurrent infections.[4]

Part III: Risk factors​

PopulationRisk factors
PremenopausalSexual intercourse ≥3× / week, spermicide use, new / multiple sex partners, UTI before age 15, history of UTI in first-degree female relative
PostmenopausalVaginal atrophy / hypoestrogenism, urinary incontinence, cystocele, elevated postvoid residual, prior UTI history
GeneticBlood-group antigen non-secretor phenotype, P1 phenotype, lower CXCR1 (IL-8 receptor) expression, family history of UTI in first-degree female relatives
Not establishedPrecoital / postcoital voiding patterns, wiping patterns, specific beverage types, tampon use, douching, hot tub use, type of underwear, BMI
[1][2][3]

Part IV: Diagnosis​

The 2025 AUA / CUA / SUFU guideline update emphasizes several key diagnostic principles:[3][1][14]

Urine testing. Obtain urinalysis and culture with susceptibility testing during each symptomatic acute cystitis episode, before treatment when feasible. Document symptoms together with pyuria and uropathogenic bacteria; an isolated positive culture or one historical culture does not explain every subsequent episode. Interpret colony count in the clinical and collection context, and repeat a contaminated specimen.[3]

Urinalysis. The 2025 update highlights the value of a negative urinalysis to lower the probability of acute cystitis in the index population. Interpret it with symptoms, sample quality and clinical context; neither bacteriuria alone nor a negative test is an automatic treatment decision.[3]

Distinguishing relapse vs. reinfection:[5]

  • Reinfection — commonly used for a different organism or a later recurrence after apparent resolution. Timing and organism identity do not prove that bacteria originated outside the urinary tract.
  • Relapse / persistence — same organism within 2 weeks; suggests occult source (calculi, diverticula, foreign body) requiring further evaluation.

Part V: Role of imaging and cystoscopy​

ACR 2026 distinguishes uncomplicated, complicated and pregnant populations; AUA uncomplicated-rUTI guidance supports selective investigation:[5][15][16]

Uncomplicated rUTI (no risk factors) — imaging is usually not appropriate. Routine cystoscopy yields few management-changing abnormalities in otherwise uncomplicated cases; reserve it for a specific indication rather than using a blanket screening strategy.[5][16]

Complicated rUTI or red flags — imaging should be considered when:[5][15]

  • Rapid recurrence within 2 weeks (relapse / persistence).
  • Nonresponse to conventional therapy.
  • Hematuria persisting after infection resolution.
  • Known risk factors (calculi, prior surgery, anatomic abnormalities, pneumaturia, fecaluria).
  • Select imaging for the suspected cause: ultrasound is a reasonable screen, and CT urography provides comprehensive assessment when appropriate. In pregnancy, use ultrasound first and noncontrast MRI selectively; avoid treating all complicated presentations as a universal CTU/MRU indication.[15]

Flowmetry and postvoid residual (PVR) — useful when impaired emptying is suspected. In a retrospective two-hospital referral cohort, abnormalities occurred in 134 / 593 women; diagnostic testing changed treatment in 117, mostly because of flow/PVR findings. Absent follow-up data, this does not prove improved outcomes from routine testing of every woman.[16]

Part VI: Treatment of acute episodes​

Treatment of an acute rUTI episode follows the same principles as sporadic uncomplicated cystitis:[1][2][17]

First-line agents (per IDSA / AUA guidelines):

Choose nitrofurantoin, TMP-SMX or fosfomycin according to cultures, local resistance, allergy and renal function, using the shortest appropriate course. Use the UTI treatment antibiotics hub for dosing; prevention and acute-treatment regimens are different.[3][17][18]

Part VII: Prevention — non-antibiotic strategies​

The 2025 AUA / CUA / SUFU update expands counselling on non-antibiotic preventive options alongside discussion of antibiotic benefits and harms.[3][19][4]

A. Vaginal estrogen (postmenopausal women) — first-line​

The AUA / CUA / SUFU guideline issues a Moderate Recommendation that peri- and postmenopausal women with rUTI should receive vaginal estrogen therapy to reduce future UTIs, if no contraindication exists.[14]

  • Raz and Stamm (1993) — landmark NEJM placebo-controlled trial of intravaginal estriol; cumulative protection from UTI markedly higher in the estrogen group than placebo, establishing topical estrogen as a foundational rUTI-prevention strategy in postmenopausal women.[22]
  • Meta-analysis of 5 RCTs (1,936 patients) — vaginal estrogen reduced rUTIs by 58% (RR 0.42; 95% CI 0.30–0.59) compared with placebo. Oral estrogen showed no benefit (RR 1.11; 95% CI 0.92–1.35).[20]
  • Tan-Kim et al. (2023) — in 5,638 women prescribed vaginal estrogen for rUTI, UTI frequency decreased by 51.9% (from 3.9 to 1.8 episodes / year; p<0.001).[21]

Formulations. Choose cream, low-dose ring or insert according to preference, feasibility and product-specific safety. Use the vaginal-estrogen prescribing hub for loading and maintenance regimens.[23]

Application update (TAPER, July 2026): a small randomized trial supports discussing periurethral cream when intravaginal applicator use is difficult, with a wide noninferiority margin. See the estrogen hub for regimens, results, and limitations.[35]

B. Methenamine hippurate​

AUA 2025 permits methenamine hippurate prophylaxis for women with rUTI (Conditional Recommendation, Grade C). It is a urinary antiseptic that can reduce reliance on daily antibiotics; it is not resistance-proof. Do not routinely add vitamin C. For the regimen, contraindications, and pH/label distinction, use the methenamine prescribing hub.[3][24][27]

  • ALTAR trial (Harding et al., 2022; n = 240) — multicenter RCT demonstrated methenamine hippurate non-inferior to daily low-dose antibiotics for rUTI prevention (1.38 vs. 0.89 episodes / person-year; absolute difference 0.49, within the predefined non-inferiority margin of 1 UTI / person-year). During treatment, resistance to at least one antibiotic in E. coli from perineal swabs was found in 46/64 antibiotic participants versus 39/70 methenamine participants (72% vs. 56%; p = 0.05). This is a colonization endpoint, not the proportion of all UTIs resistant to treatment.[24][25]
  • ImpresU trial (Heltveit-Olsen et al., 2025; 289 women recruited, 281 analyzed; age ≥70 years) — methenamine hippurate reduced antibiotic treatments for UTI by 25% during the 6-month treatment period (IRR 0.75; 95% CI 0.57–1.0; p = 0.049). After discontinuation, the methenamine group had a higher incidence of antibiotic-treated episodes during the six-month follow-up (IRR 1.7; 95% CI 1.3–2.3).[26]
  • Emerging concern. Hodgkinson et al. (2026) identified growth above the study-defined formaldehyde threshold in 11/191 ALTAR-derived E. coli isolates (5.8%), with frmR variants or plasmid mechanisms. The genomic and laboratory findings support possible resistance evolution; 5.8% is an isolate proportion, not a clinical methenamine-failure rate.[27]

C. Cranberry products​

A network meta-analysis of 50 RCTs (10,495 subjects) found cranberry products reduced UTI incidence by 28% (RR 0.72; 95% CI 0.60–0.87) compared with placebo.[28] The WikiGuidelines consensus (2024) provides a clear recommendation supporting cranberry for rUTI prevention in women, children, and individuals susceptible to UTIs after interventions.[29] Cochrane 2023 supports cranberry for women with rUTI (8 trials, 1,555 participants; RR 0.74, 95% CI 0.55–0.99), but direct comparisons with antibiotics remain too limited to establish superiority or equivalence. Optimal product and dose remain uncertain.[36]

D. D-mannose​

AUA/CUA/SUFU 2025: counsel that D-mannose alone may not prevent recurrence. Favorable rankings from older/smaller trials in a network meta-analysis should not outweigh the large blinded MERIT trial.[3][28]

However, the MERIT RCT (Hayward et al., 2024; JAMA Intern Med) — the first large, placebo-controlled trial — found that D-mannose 2 g daily for 6 months did not significantly reduce UTI recurrence vs. placebo in a primary-care population. The authors concluded that the evidence does not support recommending D-mannose for rUTI prevention.[6]

E. Probiotics​

Lactobacillus-containing probiotics reduced UTI incidence by 31% (RR 0.69; 95% CI 0.50–0.94) in the network meta-analysis.[28] Older consensus discussions considered probiotics,[23] but AUA 2025 cannot recommend Lactobacillus prophylaxis because consistent benefit and access to the studied strains remain uncertain. A favourable pooled estimate does not establish efficacy of an over-the-counter product.[3]

F. Behavioral modifications​

  • Discuss increased water intake in women drinking less than 1.5 L/day when clinically appropriate; individualize for fluid restrictions.
  • Do not present postcoital voiding or hygiene changes as proven prevention.
  • Avoidance of spermicidal contraceptives.[5][19]

G. Immunoprophylaxis​

  • MV140 has randomized evidence: a placebo-controlled trial allocated 240 women to three or six months of vaccine or placebo. During the nine-month efficacy period after the first three months, UTI-free proportions were 56%, 58% and 25%, respectively. This supports efficacy in the studied population, without establishing superiority to standard prophylaxis.[37]
  • EAU 2026 recommends immunomodulatory prophylaxis only within a well-regulated clinical trial (weak recommendation), reflecting limited and heterogeneous evidence. OM-89 and MV140 are different products; positive pooled vaccine results do not validate every preparation. Older guideline comparisons should not substitute for this current recommendation.[30][38]

Part VIII: Prevention — antibiotic prophylaxis​

AUA 2025 permits antibiotic prophylaxis after discussing benefits, harms and alternatives (Conditional Recommendation, Grade B). EAU recommends it after unsuccessful non-antimicrobial approaches; distinguish these guideline frameworks.[3][38]

Continuous or intercourse-associated prophylaxis​

Discuss expected benefits, drug toxicity, resistance, previous cultures and preferences. Continuous prophylaxis may suit infections without a consistent trigger; postcoital prophylaxis can limit exposure when recurrences track intercourse. The guideline does not require failure of every non-antibiotic option before this discussion.[3][17][2]

Use the UTI suppressive/prophylactic antibiotics hub for agent selection, regimens, monitoring and contraindications. Fluoroquinolones are not routine prophylaxis.[3]

Trials generally evaluated 6–12 months; periodically reassess ongoing need. Recurrence may return after stopping. Years of use should not be described as proven safe or resistance-free. Treat an active episode, but do not require a routine negative test-of-cure culture in an asymptomatic patient before prevention.[3][29]

Part IX: Special populations​

Postmenopausal women — include vaginal estrogen when appropriate and discuss the other preventive options according to eligibility and preference:[19][14][21]

  1. Vaginal estrogen (first-line).
  2. Non-antibiotic prevention (prescription methenamine or cranberry products, according to eligibility).
  3. Antibiotic prophylaxis when its benefits, risks and patient preferences support it.

Women with anatomic / functional abnormalities — cystocele, elevated PVR, urethral diverticula, or mesh erosion require targeted evaluation and treatment of the underlying condition.[5][32]

Antibiotic-resistant infections — multidisciplinary management involving infectious-disease specialists is recommended. Selected intravesical therapies may limit systemic drug exposure, but evidence is heterogeneous and resistance can still emerge.[31]

Part X: Emerging therapies​

A. Bacteriophage therapy​

The 2024 ELIMINATE part 1 report described 39 women in an uncontrolled, open-label phase II dose-finding study of LBP-EC01 plus TMP-SMX. No serious adverse events occurred, but higher intravenous doses produced tolerability signals and the protocol changed. Clinical and bacterial clearance in 16 evaluable participants cannot establish phage efficacy separately from the concurrent antibiotic. This remains investigational evidence.[7]

Joshi et al. (2026) showed that lytic phage ΦHP3 reduced UPEC adhesion and invasion of vaginal and bladder epithelial cells in vitro, and daily intravaginal phage administration significantly reduced vaginal UPEC burden in humanized-microbiota mice.[33]

B. UTI vaccines​

See immunoprophylaxis for the MV140 randomized trial and current EAU restriction. A network estimate combining different vaccine preparations (RR 0.65, 95% CI 0.52–0.82) does not establish class-wide effectiveness or routine availability.[28][31][38]

C. Fecal microbiota transplantation (FMT)​

Initial findings suggest FMT may interrupt the rUTI cycle by restoring a healthy gut microbiome and reducing intestinal colonization with uropathogenic organisms, though clinical data remain preliminary.[34]

D. Intravesical therapies​

Intravesical glycosaminoglycan (GAG) layer replenishment (hyaluronic acid ± chondroitin sulfate) aims to restore the protective bladder lining. Some evidence supports reduced UTI recurrence, though data quality is limited.[19][31]

Part XI: Management algorithm​

Based on the 2025 AUA / CUA / SUFU update and multisociety consensus:[3][1][23][19]

  1. Confirm the diagnosis — relate recurrent acute symptoms to pyuria and uropathogenic bacteria; obtain urine testing for each acute episode and rule out other causes of LUTS.
  2. Treat the acute episode — short-course antibiotics (nitrofurantoin, TMP-SMX, or fosfomycin).
  3. Identify and modify risk factors — spermicide avoidance, behavioral modifications, adequate hydration.
  4. Discuss preventive choices:
    • Postmenopausal — vaginal estrogen (first-line) ± methenamine hippurate ± cranberry.
    • Premenopausal — behavioral modifications, cranberry, consider methenamine hippurate.
  5. Antibiotic strategies when selected after counselling:
    • Intercourse-related — postcoital single-dose prophylaxis.
    • Non-intercourse-related — continuous prophylaxis with planned review.
    • Selected reliable patients may use self-start treatment while awaiting a culture; do not impose an arbitrary ≤2-episode annual cutoff.
  6. Further evaluation (if refractory):
    • Flowmetry and PVR measurement.
    • Imaging (CTU / MRU) if complicated features present.
    • Cystoscopy only if red flags (hematuria, suspected structural abnormality).
    • Multidisciplinary referral (urology, infectious disease, urogynecology).

Part XII: Key paradigm shifts (2025 update)​

The 2025 AUA / CUA / SUFU guideline update and contemporary reviews highlight several important shifts:[3][4]

  • Avoid treating microbial detection alone — protect against unnecessary antibiotics while treating symptomatic infection. Microbiome mechanisms do not establish routine microbiome testing or a validated microbiome-directed treatment.
  • More preventive choices — vaginal estrogen, methenamine and cranberry can reduce antibiotic exposure; prophylaxis selection remains a shared decision, not a mandatory sequence.
  • From microbial detection to clinical judgment — a negative urinalysis lowers the likelihood of acute cystitis in the index population; treatment decisions should weigh individual risks and benefits rather than relying solely on culture results.
  • From routine cystoscopy to selective evaluation — cystoscopy and imaging are reserved for complicated presentations, not routine rUTI.
  • Antimicrobial stewardship — recognition that repetitive antibiotic use causes "collateral damage" — rising resistance, microbiome disruption, and adverse effects — driving the search for alternatives.

Selected evidence​

ALTAR · 2022[24]; MERIT · 2024[6]. The comparison below preserves the study-specific population, denominator, endpoint and uncertainty.

Selected studies, not a systematic review. Outcomes and populations differ; percentages across studies should not be ranked as if they were directly comparable. These source checks do not record a clinician review of the full article.

Recurrent UTI in women — key study comparisons
Study and populationComparison and resultsUse and limitations
ALTAR · 2022

Adult women with recurrent UTI for whom prophylaxis was indicated; excluded neurogenic dysfunction and correctable urinary abnormalities.

Randomized n=240

Source and methods: ALTAR · 2022
Source
Harding C et al. Alternative to Prophylactic Antibiotics for the Treatment of Recurrent Urinary Tract Infections in Women: Multicentre, Open Label, Randomised, Non-inferiority Trial (2022). DOI: 10.1136/bmj-2021-0068229
Design
Open-label randomized noninferiority trial
Denominators
120 randomized per group; modified intention-to-treat primary analysis required ≥6 months follow-up.
Follow-up
12 months treatment plus 6 months off treatment
Source access
Selected full-text methods/results and source metadata; checked 2026-09-11.
Corrections and retractions
No notice identified in the checked metadata. No linked correction/retraction notice found in the Europe PMC indexed record. This metadata check is not an exhaustive publisher review. Checked 2026-09-11.
Methenamine hippurate vs daily low-dose antibiotic prophylaxis

Symptomatic antibiotic-treated UTI episodes per person-year · 12 months treatment

1.38 with methenamine vs 0.89 with antibiotics.

Absolute difference 0.49 episodes/year; 90% CI 0.15–0.84; prespecified noninferiority margin 1 episode/year.

An antibiotic-sparing option after shared decisions; check the drug hub for contraindications and dosing.

  • Open label; noninferiority allows some extra infections and is not equivalence.
  • Does not establish safety in label-contraindicated renal/hepatic disease or benefit from adding vitamin C.
MERIT · 2024

Adult women with recurrent UTI at 99 UK primary-care centres.

Randomized n=598

Source and methods: MERIT · 2024
Source
Hayward G et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial (2024). DOI: 10.1001/jamainternmed.2024.0264
Design
Double-blind randomized placebo-controlled trial
Denominators
303 assigned d-mannose, 295 placebo; primary outcome available in 294 and 289.
Follow-up
6 months
Source access
Selected full-text methods/results and source metadata; checked 2026-09-11.
Corrections and retractions
No notice identified in the checked metadata. No linked correction/retraction notice found in the Europe PMC indexed record. This metadata check is not an exhaustive publisher review. Checked 2026-09-11.
Daily d-mannose vs placebo

At least one medically attended clinically suspected UTI · 6 months

150/294 (51.0%) vs 161/289 (55.7%).

Risk difference −5 percentage points; 95% CI −13 to 3; P=.26.

Do not routinely recommend d-mannose for prevention in this population.

  • Primary outcome was clinically suspected, not necessarily culture-confirmed, UTI.
  • Results do not support routine prophylaxis; absence of statistical significance does not prove a zero effect.

See Also​

References​

1. Advani SD, Thaden JT, Perez R, et al. "State-of-the-art review: recurrent uncomplicated urinary tract infections in women." Clin Infect Dis. 2025;80(3):e31–e42. doi:10.1093/cid/ciae653

2. Arnold JJ, Hehn LE, Klein DA. "Common questions about recurrent urinary tract infections in women." Am Fam Physician. 2016;93(7):560–569.

3. Ackerman AL, Bradley M, D'Anci KE, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA / CUA / SUFU guideline (2025)." J Urol. 2025. doi:10.1097/JU.0000000000004723

4. Siddiqui NY, Bradley MS. "Updates in clinical management of recurrent urinary tract infections." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006060

5. Venkatesan AM, Oto A, Allen BC, et al. "ACR Appropriateness Criteria® recurrent lower urinary tract infections in females." J Am Coll Radiol. 2020;17(11S):S487–S496. doi:10.1016/j.jacr.2020.09.003

6. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

7. Kim P, Sanchez AM, Penke TJR, et al. "Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial." Lancet Infect Dis. 2024;24(12):1319–1332. doi:10.1016/S1473-3099(24)00424-9

8. Hooton TM. "Uncomplicated urinary tract infection." N Engl J Med. 2012;366(11):1028–1037. doi:10.1056/NEJMcp1104429

9. Hannan TJ, Totsika M, Mansfield KJ, et al. "Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection." FEMS Microbiol Rev. 2012;36(3):616–648. doi:10.1111/j.1574-6976.2012.00339.x

10. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. "Detection of intracellular bacterial communities in human urinary tract infection." PLoS Med. 2007;4(12):e329. doi:10.1371/journal.pmed.0040329

11. Sharma K, Thacker VV, Dhar N, et al. "Early invasion of the bladder wall by solitary bacteria protects UPEC from antibiotics and neutrophil swarms in an organoid model." Cell Rep. 2021;36(3):109351. doi:10.1016/j.celrep.2021.109351

12. Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA. "Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs." PLoS One. 2014;9(3):e93327. doi:10.1371/journal.pone.0093327

13. DiBiasio EC, Ranson HJ, Johnson JR, et al. "Peptidoglycan sensing prevents quiescence and promotes quorum-independent colony growth of uropathogenic Escherichia coli." J Bacteriol. 2020;202(20):e00157-20. doi:10.1128/JB.00157-20

14. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA / CUA / SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

15. Expert Panel on Urological Imaging, Ward RD, Allen BC, et al. "ACR Appropriateness Criteria® recurrent lower urinary tract infections in females: update 2026." J Am Coll Radiol. 2026. doi:10.1016/j.jacr.2026.03.006

16. Pat JJ, Steffens MG, Witte LPW, Marcelissen TAT, Blanker MH. "Comparison of the diagnostic yield of routine versus indicated flowmetry, ultrasound and cystoscopy in women with recurrent urinary tract infections." Int Urogynecol J. 2022;33(8):2283–2289. doi:10.1007/s00192-021-04871-2

17. Fihn SD. "Acute uncomplicated urinary tract infection in women." N Engl J Med. 2003;349(3):259–266. doi:10.1056/NEJMcp030027

18. Stamm WE, Hooton TM. "Management of urinary tract infections in adults." N Engl J Med. 1993;329(18):1328–1334. doi:10.1056/NEJM199310283291808

19. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria®." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

20. Chen YY, Su TH, Lau HH. "Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials." Int Urogynecol J. 2021;32(1):17–25. doi:10.1007/s00192-020-04397-z

21. Tan-Kim J, Shah NM, Do D, Menefee SA. "Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women." Am J Obstet Gynecol. 2023;229(2):143.e1–143.e9. doi:10.1016/j.ajog.2023.05.002

22. Raz R, Stamm WE. "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections." N Engl J Med. 1993;329(11):753–756. doi:10.1056/NEJM199309093291102

23. Smith AL, Brown J, Wyman JF, et al. "Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations." J Urol. 2018;200(6):1174–1191. doi:10.1016/j.juro.2018.04.088

24. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

25. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

26. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025. doi:10.1016/j.cmi.2025.07.006

27. Hodgkinson NC, Al-Rubaye T, Reed TCP, et al. "Implications for methenamine hippurate use in recurrent urinary tract infection management: formaldehyde resistance and altered urinary composition." PLoS Pathog. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

28. Han Z, Yi X, Li J, Liao D, Ai J. "Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials." Infection. 2025;53(2):535–546. doi:10.1007/s15010-024-02357-z

29. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines Group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

30. Kwok M, McGeorge S, Mayer-Coverdale J, et al. "Guideline of guidelines: management of recurrent urinary tract infections in women." BJU Int. 2022;130(Suppl 3):11–22. doi:10.1111/bju.15756

31. Sze C, Attia S, Zimmern P. "Effective risk-reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections." Expert Opin Pharmacother. 2025. doi:10.1080/14656566.2025.2584405

32. Nosseir SB, Lind LR, Winkler HA. "Recurrent uncomplicated urinary tract infections in women: a review." J Womens Health (Larchmt). 2012;21(3):347–354. doi:10.1089/jwh.2011.3056

33. Joshi B, Zulk JJ, Serchejian C, et al. "Bacteriophage-mediated reduction of uropathogenic E. coli from the urogenital epithelium." Infect Immun. 2026;94(4):e0054325. doi:10.1128/iai.00543-25

34. Zare M, Vehreschild MJGT, Wagenlehner F. "Management of uncomplicated recurrent urinary tract infections." BJU Int. 2022;129(6):668–678. doi:10.1111/bju.15630

35. Zuo SW, Mowers EE, Hem S, et al. "Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial." Obstet Gynecol. Published online July 27, 2026. doi:10.1097/AOG.0000000000006376

36. Williams G, Stothart CI, Hahn D, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2023;11:CD001321. doi:10.1002/14651858.CD001321.pub7

37. Lorenzo-Gómez MF, Foley S, Nickel JC, et al. "Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections." NEJM Evid. 2022;1(4):EVIDoa2100018. doi:10.1056/EVIDoa2100018

38. European Association of Urology. Guidelines on Urological Infections. 2026. Recurrent cystitis recommendations.